This study involved three major activities in estimating the historic, current, and forecasted size of the GLP-1 Analogues market. Exhaustive secondary research was carried out to collect information on the market, and its peer markets. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. A bottom-up approach was employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments.
Secondary Research
The secondary sources referred to for this research study include publications from public sources, such as the World Health Organization (WHO), National Institutes of Health (NIH), United States Food and Drug Administration (US FDA), European Medicines Agency (EMA), National Center for Biotechnology Information (NCBI), BioPharm International, World Obesity Federation, International Diabetes Federation, ScienceDirect, ClinicalTrials.gov, among others. Secondary sources also include business magazines and research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global GLP-1 Analogue market, which was validated through primary research.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify critical qualitative and quantitative information as well as assess the prospects of the market. Various primary sources from both the supply and demand side of the market were interviewed to obtain qualitative and quantitative information.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
A bottom-up approach was used to estimate and validate the total size of the GLP-1 Analogues market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
-
The list of approved GLP-1 analogues was identified through extensive secondary and primary research.
-
The revenues generated from these GLP-1 Analogues have been determined through annual reports, and secondary sources (including paid database)
-
The products were mapped as per the segments of the market. Percentage shares, splits were determined based on the revenue contributed to each of the segments. This was verified using secondary sources and by industry experts
Global GLP-1 Analogue Market Size: Bottom-up Approach
To know about the assumptions considered for the study, Request for Free Sample Report
Data Triangulation
After arriving at the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Glucagon-like peptide 1 (GLP-1) Analogues, alternatively termed GLP-1 receptor agonists, are drugs designed to mimic the incretin hormone glucagon-like peptide-1 (GLP-1). These drugs are primarily used for the treatment of type 2 diabetes mellitus and, more recently, obesity. They stimulate insulin secretion, inhibit glucagon release, and slow gastric emptying, which aids in lowering blood sugar levels and promotes satiety. This market is for these GLP-1 Analogues administered as a single drug or in combination with other receptor agonists, such as insulin.
Key Stakeholders
-
Pharmaceutical & biotechnology companies
-
Hospitals
-
Specialty clinics
-
Long-term care facilities
-
Academic researchers and government research organizations
-
Private research institutes
-
Contract manufacturing organizations (CMOs)
-
Contract research organizations (CROs)
-
Venture capitalists
Report Objectives
-
To define, describe, and forecast the global GLP-1 Analogues market by product, format, route of administration, indication, end user, and region
-
To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall GLP-1 Analogue market
-
To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
-
To provide detailed information regarding the major factors influencing the market growth, such as drivers, restraints, opportunities, and challenges
-
To forecast the size of the market segments with respect to six main regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
-
To strategically analyze the market structure and profile the key players of the global GLP-1 Analogues market and comprehensively analyze their core competencies2
-
To track and analyze competitive developments such as expansions, acquisitions, partnerships, collaborations, agreements, and product launches in the GLP-1 Analogues market
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Geographical Analysis
-
Further breakdown of the Rest of Europe GLP-1 analogues market, by country
-
Further breakdown of the Rest of Asia Pacific GLP-1 analogues market, by country
-
Further breakdown of the Rest of Latin America GLP-1 analogues market, by country
Segment Analysis
-
Further breakdown of the therapeutic indication segment as per the product portfolio of prominent players operating in the market
Customization
-
The following customization options are available for the report:
-
Analysis on CDMO services for GLP-1 analogues and other preclinical and clinical GLP-1 analogues services
Growth opportunities and latent adjacency in GLP-1 Analogues Market